Patents by Inventor Wolfgang Wurst

Wolfgang Wurst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10214723
    Abstract: The present invention relates to a method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte: (a) a clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9 protein) or a nucleic acid molecule encoding said Cas9 protein; and (b-i) a target sequence specific CRISPR RNA (crRNA) and a trans-activating crRNA (tracr RNA) or a nucleic acid molecule encoding said RNAs; or (b-ii) a chimaeric RNA sequence comprising a target sequence specific crRNA and tracrRNA or a nucleic acid molecule encoding said RNA; wherein the Cas9 protein introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) form a protein/RNA complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: February 26, 2019
    Assignee: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT
    Inventors: Ralf Kühn, Wolfgang Wurst, Oskar Ortiz Sanchez
  • Patent number: 9783780
    Abstract: The present invention relates to a method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte: (a) a clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9 protein) or a nucleic acid molecule encoding said Cas9 protein; and (b-i) a target sequence specific CRISPR RNA (crRNA) and a trans-activating crRNA (tracr RNA) or a nucleic acid molecule encoding said RNAs; or (b-ii) a chimaeric RNA sequence comprising a target sequence specific crRNA and tracrRNA or a nucleic acid molecule encoding said RNA; wherein the Cas9 protein introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) form a protein/RNA complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: October 10, 2017
    Assignee: HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT
    Inventors: Ralf Kühn, Wolfgang Wurst, Oskar Ortiz Sanchez
  • Publication number: 20160319242
    Abstract: The present invention relates to a method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte: (a) a clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9 protein) or a nucleic acid molecule encoding said Cas9 protein; and (b-i) a target sequence specific CRISPR RNA (crRNA) and a trans-activating crRNA (tracr RNA) or a nucleic acid molecule encoding said RNAs; or (b-ii) a chimaeric RNA sequence comprising a target sequence specific crRNA and tracrRNA or a nucleic acid molecule encoding said RNA; wherein the Cas9 protein introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) form a protein/RNA complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence.
    Type: Application
    Filed: July 13, 2016
    Publication date: November 3, 2016
    Inventors: Ralf KÜHN, Wolfgang WURST, Oskar ORTIZ SANCHEZ
  • Publication number: 20150376652
    Abstract: The present invention relates to a method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte: (a) a clustered, regularly interspaced, short palindromic repeats (CRISPR)-associated protein 9 (Cas9 protein) or a nucleic acid molecule encoding said Cas9 protein; and (b-i) a target sequence specific CRISPR RNA (crRNA) and a trans-activating crRNA (tracr RNA) or a nucleic acid molecule encoding said RNAs; or (b-ii) a chimaeric RNA sequence comprising a target sequence specific crRNA and tracrRNA or a nucleic acid molecule encoding said RNA; wherein the Cas9 protein introduced in (a) and the RNA sequence(s) introduced in (b-i) or (b-ii) form a protein/RNA complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence.
    Type: Application
    Filed: August 26, 2015
    Publication date: December 31, 2015
    Inventors: Ralf KÜHN, Wolfgang WURST, Oskar ORTIZ SANCHEZ
  • Patent number: 9085767
    Abstract: The present invention relates to a novel class of gene trap vector (enhanced gene trap vectors, eGTV) for efficiently identifying silent or weakly expressed target genes in mammalian genomes, methods of their production and methods for identifying and mutating target genes by using the enhanced gene trap vectors. The gene trap vectors of the present invention can also be used for inducing the expression of silent genes and enhancing the expression of weakly expressed genes. The use of the enhanced gene trap vectors for creating transgenic organisms to identify gene function and to validate pharmaceutical compounds prior to clinical applications is a further aspect of the present invention.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: July 21, 2015
    Assignees: FRANKGEN BIOTECHNOLOGIE AG, GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH, MPG MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Harald Von Melchner, Frank Schnütgen, Wolfgang Wurst, Patricia Ruiz
  • Publication number: 20140304847
    Abstract: The present invention relates to a method for modifying a target sequence in the genome of a mammalian cell, the method comprising the step of introducing into a mammalian cell: a. one or more compounds that introduce double-strand breaks in said target sequence; b. one or more DNA molecules comprising a donor DNA sequence to be incorporated by homologous recombination into the genomic DNA of said mammalian cell within said target sequence, wherein said donor DNA sequence is flanked upstream by a first flanking element and downstream by a second flanking element, wherein said first and second flanking element are different and wherein each of said first and second flanking sequence are homologous to a continuous DNA sequence on either side of the double-strand break introduced by said one or more compounds of a. within said target sequence in the genome of said mammalian cell; and c.
    Type: Application
    Filed: June 6, 2012
    Publication date: October 9, 2014
    Inventors: Ralf Kühn, Wolfgang Wurst
  • Patent number: 8530168
    Abstract: The present invention relates to a fusion protein comprising a Caspase domain or a functionally active variant thereof and a ligand binding domain of a nuclear hormone receptor, a nucleic acid coding for the fusion protein, a vector or cell comprising the nucleic acid, a method of producing the fusion protein, a non-human transgenic animal containing the nucleic acid, the use of the fusion protein for ligand-mediated induction of apoptosis of a cell, or for studying the function of a cell, tissue and/or organ or the use of a transgenic organism for studying the function of a cell at various developmental stages or as a disease model, a method for inducing apoptosis of a cell expressing a fusion protein or for identifying a ligand, or a medicament comprising a fusion protein, the nucleic acid, the vector or the cell, particularly for the treatment of cancer or for or after transplantation, particularly as safety mechanism.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: September 10, 2013
    Assignee: Helmholtz Zentrum Munich Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH)
    Inventors: Yuanyuan Chu, Ralf Kuehn, Wolfgang Wurst
  • Publication number: 20130212725
    Abstract: The present invention relates to a method of modifying a target sequence in the genome of a eukaryotic cell, the method comprising the step: (a) introducing into the cell a fusion protein comprising a DNA-binding domain of a Tal effector protein and a non-specific cleavage domain of a restriction nuclease or a nucleic acid molecule encoding the fusion protein in expressible form, wherein the fusion protein specifically binds within the target sequence and introduces a double strand break within the target sequence. The present invention further relates to the method of the invention, wherein the modification of the target sequence is by homologous recombination with a donor nucleic acid sequence further comprising the step: (b) introducing a nucleic acid molecule into the cell, wherein the nucleic acid molecule comprises the donor nucleic acid sequence and regions homologous to the target sequence.
    Type: Application
    Filed: June 7, 2011
    Publication date: August 15, 2013
    Applicant: HELMHOLTZ ZENTRUM MUNCHEN DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND
    Inventors: Ralf Kühn, Wolfgang Wurst, Melanie Meyer
  • Publication number: 20120276537
    Abstract: The present invention relates to a method of modifying a target sequence in the genome of a mammalian or avian oocyte by homologous recombination with a donor nucleic acid sequence, the method comprising the steps (a) introducing into the oocyte a zinc finger nuclease or a nucleic acid molecule encoding the zinc finger nuclease in expressible form, wherein the zinc finger nuclease specifically binds within the target sequence and introduces a double strand break within the target sequence; and (b) introducing a nucleic acid molecule into the oocyte, wherein the nucleic acid molecule comprises the donor nucleic acid sequence and regions homologous to the target sequence. The present invention further relates to a method of producing a non-human mammal or an avian carrying a modified target sequence in its genome.
    Type: Application
    Filed: October 28, 2010
    Publication date: November 1, 2012
    Inventors: Ralf Kühn, Wolfgang Wurst, Melanie Meyer
  • Publication number: 20110061118
    Abstract: The present invention relates to a DNA molecule comprising: (a) a first DNA sequence comprising: (aa) a coding sequence giving rise upon transcription to a factor that contributes to the reprogramming of a somatic cell into an induced pluripotent stem (iPS) cell; (ab) a promoter mediating the transcription of said coding sequence; and (ac) two sequence motifs that mediate excision of (aa) and/or (ab) from the DNA molecule, wherein one sequence motif is positioned 5? and the other sequence motif is positioned 3? of the sequence to be excised; (b) a second DNA sequence comprising a sequence motif that mediates site-specific integration of (a) into another DNA molecule.
    Type: Application
    Filed: March 17, 2009
    Publication date: March 10, 2011
    Applicant: Helmholtz Zentrum Munchen
    Inventors: Ralf Kühn, Wolfgang Wurst
  • Publication number: 20110023137
    Abstract: The present invention relates to a fusion protein comprising a Caspase domain or a functionally active variant thereof and a ligand binding domain of a nuclear hormone receptor, a nucleic acid coding for the fusion protein, a vector or cell comprising the nucleic acid, a method of producing the fusion protein, a non-human transgenic animal containing the nucleic acid, the use of the fusion protein for ligand-mediated induction of apoptosis of a cell, or for studying the function of a cell, tissue and/or organ or the use of a transgenic organism for studying the function of a cell at various developmental stages or as a disease model, a method for inducing apoptosis of a cell expressing a fusion protein or for identifying a ligand, or a medicament comprising a fusion protein, the nucleic acid, the vector or the cell, particularly for the treatment of cancer or for or after transplantation, particularly as safety mechanism.
    Type: Application
    Filed: June 20, 2008
    Publication date: January 27, 2011
    Applicant: HELMHOLLZ ZENLRUM MUNICH DEULSCHES FORSCHUNG FUER GESUNDHEIT AND UNWELT
    Inventors: Yuanyuan Chu, Ralf Kuehn, Wolfgang Wurst
  • Publication number: 20100299771
    Abstract: The present invention relates to a combination of DNA segments comprising: (a) a first segment comprising in 5? to 3? or 3? to 5? order: (aa) a promoter; (ab) a first DNA sequence comprising: (i) a DNA sequence giving rise upon transcription to the sense strand of an shRNA molecule; (ii) a transcriptional stop element which is flanked by a first type of recombinase recognition sequences; and (iii) a DNA sequence giving rise upon transcription to the antisense strand of an shRNA molecule; (b) a second segment comprising in 5? to 3? or 3? to 5? order: (ba) a promoter; (bb) a second DNA sequence comprising: (i) a DNA sequence giving rise upon transcription to the sense strand of an shRNA molecule; (ii) a transcriptional stop element which is flanked by a second type of recombinase recognition sequences; and (iii) a DNA sequence giving rise upon transcription to the antisense strand of an shRNA molecule; wherein (i) said first type of recombinase recognition sequences are recognized and recombined by a recombinas
    Type: Application
    Filed: September 17, 2008
    Publication date: November 25, 2010
    Applicant: HELMHOLTZ ZENTRUM MUNCHEN- DEUTSCHES FORSCHUNGZENTRUM FUR GESUNDHEIT UND UMWELT(GMBH)
    Inventors: Ralf Kühn, Wolfgang Wurst, Patricia Steuber-Buchberger
  • Publication number: 20100242127
    Abstract: The present invention relates to a method for identifying a compound capable of modulating an anxiety or depression disorder comprising the steps of: (a) contacting a composition comprising a B-Raf protein or a B-Raf gene in expressible form or a transcript thereof with a compound under conditions that allow for an interaction of the B-Raf protein or the B-Raf gene or a transcript thereof and the compound; and (b) measuring whether said interaction, if any, results in (i) a change of B-Raf kinase activity compared to B-Raf kinase activity in the absence of said compound; (ii) a modulation of the expression of the B-Raf gene compared to B-Raf gene expression in the absence of said compound; or (iii) the formation of a complex between the compound and the B-Raf protein, wherein such a change in activity, modulation of expression or the formation of a complex is indicative of the compound being a modulator of an anxiety or depression disorder.
    Type: Application
    Filed: June 3, 2008
    Publication date: September 23, 2010
    Applicant: HELMHOLTZ ZENTRUM MUNCHEN
    Inventors: Christiane Hitz, Sabine Hölter, Ralf Kühn, Wolfgang Wurst, Benedikt Wefers
  • Publication number: 20100199360
    Abstract: The present invention relates to a novel class of gene trap vector (enhanced gene trap vectors, eGTV) for efficiently identifying silent or weakly expressed target genes in mammalian genomes, methods of their production and methods for identifying and mutating target genes by using the enhanced gene trap vectors. The gene trap vectors of the present invention can also be used for inducing the expression of silent genes and enhancing the expression of weakly expressed genes. The use of the enhanced gene trap vectors for creating transgenic organisms to identify gene function and to validate pharmaceutical compounds prior to clinical applications is a further aspect of the present invention.
    Type: Application
    Filed: November 28, 2005
    Publication date: August 5, 2010
    Applicants: FRANKGEN BIOTECHNOLOGIE AG., GSF FORSCHUNGSZENTRUM FUR UMWELT UND GESUNDHEIT GMBH, MPG MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Harald Von Melchner, Frank Schnutgen, Wolfgang Wurst, Patricia Ruiz
  • Publication number: 20090113561
    Abstract: A new type of gene trap cassette, which can induce conditional mutations, relies on directional site-specific recombination systems, which can repair and re-induce gene trap mutations when activated in succession. After the gene trap cassettes are inserted into the genome of the target organism, mutations can be activated at a particular time and place in somatic cells. The gene trap cassettes also create multipurpose alleles amendable to a wide range of post-insertional modifications. Such gene trap cassettes can be used to mutationally inactivate all cellular genes temporally and/or spatially. Cells which contain the inventive gene trap cassette can be used for identification and/or isolation of genes and for the creation of transgenic organisms to study gene function at various developmental stages, including the adult, as well as for the creation of animal models of human disease useful for in vivo drug target validation.
    Type: Application
    Filed: November 28, 2005
    Publication date: April 30, 2009
    Applicant: FRANKGEN BIOTECHNOLOGIE AG
    Inventors: Harald Von Melchner, Frank Schnutgen, Wolfgang Wurst, Particia Ruiz, Silke De-Zolt, Thomas Floss, Jens Hansen
  • Publication number: 20040133933
    Abstract: This invention relates to a novel DNA sequence encoding a bHLH transcription factor in vertebrates, preferably mammals, e.g. in mice or humans, as well as the expressed transcription factor. The invention further relates to vectors containing said DNA sequences and host cells transformed by these vectors. Furthermore, the invention encompasses antibodies specific for the transcription factors as well as the use of the DNA sequences and transcription factors in the diagnosis or therapy of neurodegenerative diseases, e.g. Parkinson's disease. The present invention further relates to an ex vivo method of producing dopaminergic cells and the therapeutic use of these dopaminergic cells.
    Type: Application
    Filed: July 31, 2003
    Publication date: July 8, 2004
    Inventors: Jordi Guimera-Vilaro, Wolfgang Wurst, Daniela Vogt-Weisenhorn, Laure Bally-Cuif
  • Patent number: 6656735
    Abstract: Transcription factor responsive elements, target genes, and co-factors of a transcription factor, either individually or in combination, are identified by integrating into the genome of a eukaryotic cell a gene trap vector that includes a reporter gene, a polyadenylation site, and a selectable marker gene, selecting the cells in which the gene trap vector is successfully integrated and contacting those cells with the transcription factor, then identifying and cultivating those cells having a gene into which the gene trap vector has been integrated and in which the reporter gene activity has been altered by interaction between the transcription factor and a transcription factor responsive element of that gene, and identifying the transcription factor responsive element, target gene, or cofactor that interacts with the transcription factor.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: December 2, 2003
    Assignees: GSF Forschungszentrum Fuer Umwelt Und Gesundheit GmbH, Centre National de la Recherche Scientifique
    Inventors: Wolfgang Wurst, Alain Prochiantz
  • Patent number: 5832593
    Abstract: A splice head for use with a modular wire connector, to work with and hold the wires while installing them in the connector, particularly for wires of differing diameters. The splice head includes a coil spring loosely arranged on a bar and movable axially thereon. By selecting an appropriate location for the starting point on the spring and selection of the spring position on the bar, different sized wires can be fixed by the coils of the spring. The bar may be circular in cross-section to allow the spring to slide easily forward and backward. This construction allows simpler placement of the wires since the coil spring does not need to to replaced for wires of different sizes, and there is no requirement that the splicing operation begin at one particular end of the coil since neither end is fixed.
    Type: Grant
    Filed: April 22, 1997
    Date of Patent: November 10, 1998
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: Wolfgang Wurst, Udo Seidel
  • Patent number: 5806168
    Abstract: A tool (10) for the termination of insulated wires in electrical connectors having different heights, which tool has a mechanism affording adjustment of the spacing between a pressing body (50), accommodated by a splice head, and a retaining body for the connector. The adjustment in height between the bodies is afforded by step adjustment and by an intermediate member (56, 58) affording smaller pitches, and the tool has an attachment mechanism for releasably attaching the tool to the retaining body.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: September 15, 1998
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: Wolfgang Wurst, Eckhard Wolter
  • Patent number: 5212708
    Abstract: In an axial flow gas laser, in particular a high-power CO.sub.2 laser with DC excitation, at least one discharge tube (1) of dielectric material, in particular quartz glass, is provided. First and second connection bodies (E1, E2) are sealingly connected to the discharge tube (1) or to connection necks branching off from it, in each case in the vicinity of an electrical and laser gas connection point, forming a connection chamber (K1, K2), and are connected to laser gas inlet lines (4) or outlet lines (9). The first connection body (E1) is connected to the anode potential and the second connection body (E2) to the cathode potential of a direct voltage source. The first and second connection bodies (E1, E2) are disposed with tubular axial spacing from one another, so that the discharge tube (1), with its gas chamber, forms a discharge path between the anode and cathode potentials.
    Type: Grant
    Filed: May 29, 1990
    Date of Patent: May 18, 1993
    Assignee: Rofin-Sinar Laser GmbH
    Inventors: Klaus Schanz, Wolfgang Wurst